Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 4, 1997, Pages 347-359

  Figg, William D ^a   Christian, Michaele C ^a   Lush, Richard ^a   Link, Charles J ^a   Davis, Patricia ^a   Kohn, Elise ^a   Sarosy, Gisele ^a   Rothenberg, Mace L ^a   Weiss, Raymond B ^a   Ryan, Nathan ^a   Jacobs, Joan ^a   Reed, Eddie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AAS; ormaplatin; pharmacokinetics; phase 1; ultrafiltrate

Indexed keywords

PLATINUM; TETRAPLATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; STEADY STATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HEMOFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PLATINUM;

EID: 0030963135     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199705)18:4<347::AID-BDD23>3.0.CO;2-O     Document Type: Article

References (22)

1. W. Schmidt and S. G. Chaney, Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res., 53, 799-805 (1993).
2. R. J. Parker, J. A. Vionnet, F. Bostick-Bruton and E. Reed, Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin. Cancer Res., 53, 242-247 (1993).
3. M. A. Smith, J. H. Smith, C. L. Litterst, M. P. Copley, J. Uozumi and M. R. Boyd, In vivo biochemical indices of nephrotoxicity and platinum analogs tetraplatin, CHIP, and cisplatin in Fischer 344 rat. Fundam. Appl. Toxicol., 10, 62-72 (1988).
4. M. A. Smith, J. H. Smith, C. L. Litterst, M. P. Copley, J., Uozumi and M. Boyd, Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fisher 344 rat. Fundam. Appl. Toxicol., 10, 45-61 (1988).
5. E. Rotondo, F. Fimiani, A. Cavallaro and T. Ainis, Does the antitumoral activity of platinum (IV) derivatives result from their in vivo reduction? Tumori, 69, 31-36 (1983).
6. G. R. Gibbons, S. Wyrick and S. G. Chaney, Rapid reduction of tetrachloro-(d,1-trans)-1,2-diaminocyclohexaneplatinum (IV) (tetraplatin) in RPMI 1640 tissue culture medium. Cancer Res., 49, 1402-1407 (1989).
7. S. G. Chaney, G. Kaun-Till, A. Poma and D. J. Holbrook, Biotransformation of tetraplatin in rat plasma. Proc. Am. Assoc. Cancer Res., 30, 470 (1989).
8. H. K., Choi, A. Terzis, R. C. Stevens, R. Bau, R. Baugwitz, V. L. Narayanan and M. Wolpert-DeFilippes, Reaction products of a new anti-cancer agent, Pt(IV) cyclohexyldiamine CI4 with guanosine and 9-methylguanine: nucleobase and a nucleoside. Biochem. Biophys. Res. Commun., 156, 1120-1124 (1988).
9. E. Reed, M. Dabholkar and B. A. Chabner, Platinum analogues. In Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd edn, B. A. Chabner and D. L. Longo (Eds), Lippincott-Raven, Philadelphia, PA, 1996, pp. 357-378.
10. K. R. Harrap, Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev., 12, 21-33 (1985).
11. T. L. Cornelison and E. Reed, Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gyn. Oncol., 50, 147-158 (1993).
12. E. Reed, S. Sauerhoff and M. Poirier, Quantitation of platinum-DNA binding in human tissues following therapeutic levels of drug exposures. At. Spectrosc., 9, 93-95 (1988).
13. K. Yamaoka, J. Nakagawa and T. Uno, Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 2, 165-175 (1978).
14. M. C. Christian, W. D. Figg, E. Kohn, G. Sarosy, C. Link, P. Davis, R. Weiss and E. Reed, Pharmacokinetics of total platinum following bolus administration of ormaplatin. Proc. Am. Assoc. Cancer Res., 35, 2596 (1994).
15. W. P. Petros, S. G. Chaney, D. C. Smith, J. Fangmeier, M. Sakata, T. D. Brown and D. L. Trump, Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. Cancer Chemother. Pharmacol., 33, 347-354 (1994).
16. R. J. Schilder, F. P. LaCreta, R. P. Perez, S. W. Johnson, J. M. Brennan, A. Rogatko, S. Nash, C. McAleer, T. C. Hamilton, D. Roby, R. C. Young, R. F. Ozols and P. J. O'Dwyer, Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC363812) administered on day 1 and day 8 schedule. Cancer Res., 54, 709-717 (1994).
17. S. C. Plaxe, P. S. Braly, J. L. Freddo, E. McClay, R. D. Christen, S. Kirmani, S. Kim, D. Heath and S. B. Howell, Phase I and pharmacokinetic study of intraperitoneal ormaplatin. Gyn. Oncol., 51, 72-77 (1993).
18. T. J. O'Rourke, G. R. Weiss, P. New, H. A. Burris, G. Rodriguez, J. Eckhardt, J. Hardy, J. G. Kuhn, S. Fields, G. M. Clark and D. D. Von Hoff, Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812). Anti-Cancer Drugs, 5, 520-526 (1994).
19. E. Reed, Platinum analogs. In Cancer: Principles and Practice of Oncology, 4th edn, V. T. Devita, S. Hellman and S. A. Rosenberg (Eds), Lippincott, Philadelphia, PA, 1993, pp. 390-400.
20. B. J. Corden, R. L. Fine, R. F. Ozols and J. M. Collins, Clinical pharmacology of high-dose cisplatin. Cancer Chemother. Pharmacol., 14, 38-41 (1985).
21. S. Orguri, T. Sakakibara, H. Mase, T. Shimizu, K. Ishikawa, K. Kimura and R. D. Smyth, Clinical pharmacokinetics of carboplatin. J. Clin. Pharmacol., 28, 208-215 (1988).
22. R. B. Weiss and M. C. Christian, New cisplatin analogues in development: a review. Drugs, 46, 360-377 (1993).